These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 36387341)

  • 1. The effectiveness and safety of direct-acting antivirals for hepatitis C virus treatment: A single-center experience in Saudi Arabia.
    Alarfaj SJ; Alzahrani A; Alotaibi A; Almutairi M; Hakami M; Alhomaid N; Alharthi N; Korayem GB; Alghamdi A
    Saudi Pharm J; 2022 Oct; 30(10):1448-1453. PubMed ID: 36387341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
    J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.
    Dore GJ; Conway B; Luo Y; Janczewska E; Knysz B; Liu Y; Streinu-Cercel A; Caruntu FA; Curescu M; Skoien R; Ghesquiere W; Mazur W; Soza A; Fuster F; Greenbloom S; Motoc A; Arama V; Shaw D; Tornai I; Sasadeusz J; Dalgard O; Sullivan D; Liu X; Kapoor M; Campbell A; Podsadecki T
    J Hepatol; 2016 Jan; 64(1):19-28. PubMed ID: 26321288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct-acting antiviral therapy.
    Poordad F; Bennett M; Sepe TE; Cohen E; Reindollar RW; Everson G; Phillips RW; Siddique A; Sullivan JG; Pilot-Matias T; Abunimeh M; Cohen DE; Younes Z
    J Med Virol; 2019 Jul; 91(7):1307-1312. PubMed ID: 30840774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct-acting antiviral agents in patients with hepatitis C genotype 1-4 infections in a tertiary hospital.
    Del Rio-Valencia JC; Asensi-Diez R; Villalobos-Torres L; Muñoz Castillo I
    Rev Esp Quimioter; 2018 Jun; 31(3):226-236. PubMed ID: 29771105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China.
    Xia H; Lu C; Wang Y; Zaongo SD; Hu Y; Wu Y; Yan Z; Ma P
    Front Pharmacol; 2020; 11():710. PubMed ID: 32508646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients.
    Abdel-Moneim A; Aboud A; Abdel-Gabbar M; Zanaty M; Ramadan M
    Dig Dis Sci; 2018 May; 63(5):1341-1347. PubMed ID: 29546644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study.
    Tronina O; Durlik M; Wawrzynowicz-Syczewska M; Buivydiene A; Katzarov K; Kupcinskas L; Tolmane I; Karpińska E; Pisula A; Karwowska KM; Bolewska B; Jabłkowski M; Rostkowska K; Jakutiene J; Simonova M; Flisiak R
    Ann Transplant; 2017 Apr; 22():199-207. PubMed ID: 28386057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with direct-acting antivirals in genotype 1-5 infected chronic hepatitis C patients in Turkey.
    Sahin A; Akay O
    Ann Saudi Med; 2023; 43(5):308-314. PubMed ID: 37805816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience.
    Naguib GG; Farid A; Hassan M; Elshafie A; Shazly YE; Shaker MK; Ezzat H; Safwat E; Ahmed OA; Dabbous H; Sherief AF; Hassany M; Elserafy M; Elsayed MH
    Arab J Gastroenterol; 2021 Dec; 22(4):285-291. PubMed ID: 34531135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III).
    Shafran SD; Shaw D; Charafeddine M; Agarwal K; Foster GR; Abunimeh M; Pilot-Matias T; Pothacamury RK; Fu B; Cohen E; Cohen DE; Gane E
    J Viral Hepat; 2018 Feb; 25(2):118-125. PubMed ID: 28833938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.
    Pessoa MG; Ramalho-Madruga JV; Alves K; Nunes EP; Cheinquer H; Brandão-Mello CE; Mendes-Correa MC; Ferraz ML; Ferreira PRA; Álvares-da-Silva MR; Coelho HS; Affonso-de-Araújo ES; Furtado J; Parana R; Silva G; Lari SA; Liu L; Tripathi R; Pilot-Matias T; Cohen DE; Shulman NS; Martinelli A
    Ann Hepatol; 2018 Oct; 17(6):959-968. PubMed ID: 30600291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease.
    Sanai FM; Alghamdi AS; Afghani AA; Alswat K; AlZanbagi A; Alghamdi MN; AlMousa A; Aseeri M; Assiri AM; Babatin MA
    Liver Int; 2018 Aug; 38(8):1395-1401. PubMed ID: 29288514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis.
    Chen R; Xiong Y; Zeng Y; Wang X; Xiao Y; Zheng Y
    Front Public Health; 2023; 11():1179531. PubMed ID: 37841743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders.
    Fuchs M; Monto A; Bräu N; Charafeddine M; Schmidt W; Kozal M; Naggie S; Cheung R; Schnell G; Yu Y; Richards K; Mullally V; Cohen DE; Toro D
    J Med Virol; 2020 Dec; 92(12):3459-3464. PubMed ID: 31829433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.
    Welzel TM; Hinrichsen H; Sarrazin C; Buggisch P; Baumgarten A; Christensen S; Berg T; Mauss S; Teuber G; Stein K; Deterding K; van Bömmel F; Heyne R; John C; Zimmermann T; Lutz T; Schott E; Hettinger J; Kleine H; König B; Hüppe D; Wedemeyer H
    J Viral Hepat; 2017 Oct; 24(10):840-849. PubMed ID: 28342229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies.
    Darvishian M; Wong S; Binka M; Yu A; Ramji A; Yoshida EM; Wong J; Rossi C; Butt ZA; Bartlett S; Pearce ME; Samji H; Cook D; Alvarez M; Chong M; Tyndall M; Krajden M; Janjua NZ
    J Viral Hepat; 2020 Mar; 27(3):243-260. PubMed ID: 31664755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.
    Rockstroh JK; Orkin C; Viani RM; Wyles D; Luetkemeyer AF; Lazzarin A; Soto-Malave R; Nelson MR; Bhagani SR; Klinker HHF; Rizzardini G; Girard PM; Tural C; Shulman NS; Mobashery N; Hu YB; Fredrick LM; Pilot-Matias T; Trinh R; Gane E
    Open Forum Infect Dis; 2017; 4(3):ofx154. PubMed ID: 28948180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience.
    Muñoz-Gómez R; Rincón D; Ahumada A; Hernández E; Devesa MJ; Izquierdo S; Ortiz M; Hernández-Albujar A; Fernández-Rodríguez C; Calvo M; González R; Lozano M; Castellano G; Fernández-Vázquez I
    J Viral Hepat; 2017 Jun; 24(6):464-471. PubMed ID: 27976490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Chronic HCV Infection with the New Direct Acting Antivirals (DAA): First Report of a Real World Experience in Southern Brazil.
    Cheinquer H; Sette H; Wolff FH; de Araujo A; Coelho-Borges S; Soares SRP; Barros MFA
    Ann Hepatol; 2017; 16(5):727-733. PubMed ID: 28809742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.